Bioorthogonal Oxime Ligation Mediated In Vivo Cancer Targeting.
Bioorthogonal Oxime Ligation Mediated In Vivo Cancer Targeting.
复制标题
DOI：
10.1039/c5sc00063g
复制
发表时间：
2015-04-01
期刊：
影响因子：
8.4
通讯作者：
Cheng J
中科院分区：
文献类型：
--
作者：
Tang L;Yin Q;Xu Y;Zhou Q;Cai K;Yen J;Dobrucki LW;Cheng J
Here, we report an in vivo cancer targeting strategy mediated by bioorthogonal oxime ligation. Current cancer targeting relying on specific biological interaction between the cell surface antigen and respective antibody or its analogue has proven to be effective in the treatment of different cancers; however, this strategy has its own limitations, such as the heterogeneity of cancer cells and immunogenicity of the biomacromolecule binding ligands. Bioorthogonal chemical conjugation has emerged as an attractive alternative to biological interaction for in vivo cancer targeting. Here, we report an in vivo cancer targeting strategy mediated by bioorthogonal oxime ligation. An oxyamine group, the artificial target, is introduced onto 4T1 murine breast cancer cells through liposome delivery and fusion. Poly(ethylene glycol)-polylactide (PEG-PLA) nanoparticles (NPs) are surface-functionalized with aldehyde groups as targeting ligands. The improved in vivo cancer targeting of PEG-PLA NPs is achieved through specific and efficient chemical reaction between the oxyamine and aldehyde groups.
